These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32494207)

  • 21. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy.
    Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
    Sci Rep; 2021 Mar; 11(1):6759. PubMed ID: 33762600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term outcomes following treatment of recalcitrant cystoid macular edema secondary to radiation maculopathy using intravitreal brolucizumab.
    Corradetti G; Corvi F; Juhn A; Sadda SR
    Am J Ophthalmol Case Rep; 2020 Dec; 20():100981. PubMed ID: 33145457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aqueous vascular endothelial growth factor and clinical outcomes correlation after single intravitreal injection of bevacizumab in patients with neovascular age-related macular degeneration.
    Cabral T; Lima LH; Polido J; Duong J; Okuda É; Oshima A; Serracarbassa P; Regatieri CV; Belfort R
    Int J Retina Vitreous; 2017; 3():6. PubMed ID: 28469938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case of recalcitrant neovascular wet age-related macular degeneration treated with Intravitreal Brolucizumab.
    Panigrahi PK
    Photodiagnosis Photodyn Ther; 2021 Sep; 35():102450. PubMed ID: 34303030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of the hyperautofluorescent ring associated with choroidal neovascularisation in eyes undergoing anti-VEGF therapy for wet age-related macular degeneration.
    Camacho N; Barteselli G; Nezgoda JT; El-Emam S; Cheng L; Bartsch DU; Freeman WR
    Br J Ophthalmol; 2015 Sep; 99(9):1277-83. PubMed ID: 25777818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Hamid MA; Abdelfattah NS; Salamzadeh J; Abdelaziz STA; Sabry AM; Mourad KM; Shehab AA; Kuppermann BD
    Int J Retina Vitreous; 2021 Apr; 7(1):26. PubMed ID: 33795022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
    Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
    Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined intravitreal pharmacosurgery in patients with occult choroidal neovascularization secondary to wet age-related macular degeneration.
    Koss MJ; Scholtz S; Haeussler-Sinangin Y; Singh P; Koch FH
    Ophthalmologica; 2010; 224(2):72-8. PubMed ID: 19707030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal bevacizumab for choroidal neovascularization secondary to non-age-related macular degeneration.
    Salehipour M; Vafi N; Doozande A; Yaseri M
    J Ophthalmic Vis Res; 2010 Jan; 5(1):10-9. PubMed ID: 22737321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.
    Smith BT; Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA
    Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
    Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
    Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis.
    Hänsli C; Schild C; Pfister I; Garweg JG
    Life (Basel); 2023 Mar; 13(3):. PubMed ID: 36983970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
    Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema.
    Ünlü C; Erdogan G; Gunay BO; Kardes E; Akcay BI; Ergin A
    Int Ophthalmol; 2017 Feb; 37(1):147-158. PubMed ID: 27154721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [What can anti-VEGF therapy achieve in clinical routine? : Effectiveness of anti-VEGF therapy in patients with macular diseases in clinical routine on 1492 eyes in Austria].
    Wiesinger K; Reinelt P; Ennemoser A; Edelmayr M; Schönherr U
    Ophthalmologe; 2017 Jul; 114(7):639-645. PubMed ID: 27815675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration.
    Haug SJ; Hien DL; Uludag G; Ngoc TTT; Lajevardi S; Halim MS; Sepah YJ; Do DV; Khanani AM
    Am J Ophthalmol Case Rep; 2020 Jun; 18():100680. PubMed ID: 32258827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study.
    Ohji M; Okada AA; Sasaki K; Moon SC; Machewitz T; Takahashi K;
    Graefes Arch Clin Exp Ophthalmol; 2021 Dec; 259(12):3637-3647. PubMed ID: 34283294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
    Braimah IZ; Agarwal K; Mansour A; Chhablani J;
    Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.